Market research reports, consulting: Global Market Insights Inc.

Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > systemic lupus erythematosus treatment market

Systemic Lupus Erythematosus Treatment Market Size

Report ID: GMI10531 Published Date: July 2024Report Format: PDF
Download Free Sample
Summary
Table of Content

Systemic Lupus Erythematosus Treatment Market Size

Systemic Lupus Erythematosus Treatment Market size was valued at around USD 2.7 billion in 2023 and is estimated to grow at 7.6% CAGR from 2024 to 2032. Increasing prevalence of SLE worldwide, coupled with rising awareness about the disease, is significantly boosting the demand for effective treatment options.

 

Systemic Lupus Erythematosus Treatment Market

For instance, according to the Centers for Disease Control and Prevention (CDC), an estimated 204,000 people have SLE in the U.S., highlighting the growing need for effective treatments. This surge in SLE cases, bolstered by heightened disease awareness, is fueling the demand for more effective treatments. Moreover, increased healthcare spending, refined diagnostic tools, and governmental support for rare diseases are further catalyzing market growth.

For instance, in the last five years, the National Institutes of Health (NIH) has allocated over USD 621 million for lupus research. Further, collaborations and strategic partnerships among pharmaceutical companies are enhancing drug development pipelines, while patient-centric approaches and personalized medicine trends are ensuring tailored treatment options, collectively driving the growth of the SLE treatment market.

Systemic lupus erythematosus (SLE) treatment refers to a range of medical interventions aimed at managing and alleviating the symptoms of systemic lupus erythematosus, a chronic autoimmune disease in which the body's immune system attacks its own tissues and organs. The treatment typically involves the use of medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antimalarials, immunosuppressants, and biologics to reduce inflammation, suppress the overactive immune response, and manage pain. The goal of SLE treatment is to minimize disease activity, prevent flare-ups, and maintain the patient's quality of life, often through a personalized approach tailored to the severity and manifestations of the disease in each individual.

Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :

Why is the demand for oral systemic lupus erythematosus treatment rising?+

The oral segment in the market is anticipated to witness 7.3% CAGR between 2024-2032 due to their convenience, ease of administration, and efficacy in managing symptoms along with advancements in oral drug formulations.

What is the size of the systemic lupus erythematosus treatment market?+

Global systemic lupus erythematosus treatment industry was valued at USD 2.7 billion in 2023 and is anticipated to register 7.6% CAGR between 2024 and 2032 due to increasing prevalence worldwide and rising awareness.

Who are the leading systemic lupus erythematosus treatment industry players?+

Anthera Pharmaceuticals, Inc., Aurinia Pharmaceuticals, Inc., AstraZeneca, Biogen, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GSK plc., and ImmuPharma PLC, among others.

How big is the North America systemic lupus erythematosus treatment industry?+

North America systemic lupus erythematosus treatment market is projected to reach USD 1.9 billion by 2032, driven by robust R&D activities.

Systemic Lupus Erythematosus Treatment Market Scope

Related Reports

Buy Now

Premium Report Details

Download Free Sample